Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab
Regardless of diabetes status, the overall incidence of major adverse cardiovascular events was higher in the placebo group vs the alirocumab group.
|The following article is part of conference coverage from the American Diabetes Association's 78th Scientific Sessions (ADA 2018) in Orlando,Florida. Endocrinology Advisor's staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back for the latest news from ADA 2018.|
For more coverage of ADA 2018, click here.